Abstract
A series of 48 commercial benzaldehydes have been evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Benzaldehydes 39 and 41 exhibited a significant activity at 3.12 μg/mL. Although commercial benzaldehydes have been largely used by many research groups in search of news TB-drugs, they had not been tested previously against Mycobacterium tuberculosis. This study adds important information to the rational design of new lead anti-TB drugs.
Keywords: Antimycobacterial evaluation, Alamar Blue assay, Benzaldehydes, Cytotoxicity, Drugs, Tuberculosis, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, MDR-TB, drug-resistant tuberculosis, XDR-TB, Rifampin, Isoniazid, Cell Viability Assay, RPMI 1640, DMSO, MABA, BACTEC, SAR, Mosmans's MTT
Letters in Drug Design & Discovery
Title: Evaluation of Substituted Benzaldehydes Against Mycobacterium tuberculosis
Volume: 7 Issue: 10
Author(s): Marcelle de Lima Ferreira, Andre Luis Peixoto Candea, Maria das Gracas Muller de Oliveira Henriques, Maria Cristina Silva Lourenco, Carlos Roland Kaiser and Marcus Vinicius Nora de Souza
Affiliation:
Keywords: Antimycobacterial evaluation, Alamar Blue assay, Benzaldehydes, Cytotoxicity, Drugs, Tuberculosis, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, MDR-TB, drug-resistant tuberculosis, XDR-TB, Rifampin, Isoniazid, Cell Viability Assay, RPMI 1640, DMSO, MABA, BACTEC, SAR, Mosmans's MTT
Abstract: A series of 48 commercial benzaldehydes have been evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Benzaldehydes 39 and 41 exhibited a significant activity at 3.12 μg/mL. Although commercial benzaldehydes have been largely used by many research groups in search of news TB-drugs, they had not been tested previously against Mycobacterium tuberculosis. This study adds important information to the rational design of new lead anti-TB drugs.
Export Options
About this article
Cite this article as:
de Lima Ferreira Marcelle, Luis Peixoto Candea Andre, das Gracas Muller de Oliveira Henriques Maria, Cristina Silva Lourenco Maria, Roland Kaiser Carlos and Vinicius Nora de Souza Marcus, Evaluation of Substituted Benzaldehydes Against Mycobacterium tuberculosis, Letters in Drug Design & Discovery 2010; 7 (10) . https://dx.doi.org/10.2174/1570180811007010754
DOI https://dx.doi.org/10.2174/1570180811007010754 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Constructive Personalized Medicine: The Potential Integration of Synthetic Biology and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Synthesis and Evaluation of Morpholinoethyl Ester Conjugate of N-acetylcysteine in Ovalbumin-induced Airway Hyperresponsiveness in Sprague Dawley Rats
Letters in Drug Design & Discovery Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Editorial (Thematic Issue: Nanotechnology for Drug Delivery Applications)
Current Drug Delivery Synthesis of 2-, 3- or 4-phenylsubtituted Chalcones Based on 4- phenylamino-6-nitro-2-[(E)-2-phenylvinyl]quinoline, Evaluation of their Antimicrobial and Antifungal Activity
Letters in Drug Design & Discovery 2-Mercaptobenzothiazole and its Derivatives: Syntheses, Reactions and Applications
Current Organic Chemistry Targeting Tuberculosis Through Diversity Oriented Synthesis (DOS) of Hydrazide Frameworks and Evaluation of Mycobacterium Activity Thereof
Current Organic Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) Mycobacterial Heat Shock Proteins as Vaccines - A Model of Facilitated Antigen Presentation
Current Molecular Medicine Green and Sustainable Technology: Efficient Strategy for the Synthesis of Biologically Active Pyrimidine Derivatives
Current Organocatalysis Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective
Mini-Reviews in Medicinal Chemistry Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Early Decision: Effector and Effector Memory T Cell Differentiation in Chronic Infection
Current Immunology Reviews (Discontinued) Radiomics and Diagnostic CT-MRI
Current Medical Imaging Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Current Pharmaceutical Design Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy <i>In silico</i> Modeling of Antimalarial Protein Kinase Inhibitors
Letters in Drug Design & Discovery